Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 10:08 am Sale |
2021-12-31 | 13G | Fennec Pharmaceuticals Inc. FENC |
AVORO CAPITAL ADVISORS LLC | 1,200,000 4.600% |
-470,000 (-28.14%) |
Filing History |
| 2022-02-11 10:07 am Sale |
2021-12-31 | 13G | Avadel Pharmaceuticals plc AVDL |
AVORO CAPITAL ADVISORS LLC | 1,670,000 2.900% |
-2,695,000 (-61.74%) |
Filing History |
| 2022-02-11 10:07 am Sale |
2021-12-31 | 13G | Arena Pharmaceuticals, Inc. ARNA |
AVORO CAPITAL ADVISORS LLC | 1,235,000 2.000% |
-2,955,000 (-70.53%) |
Filing History |
| 2022-02-11 10:06 am Sale |
2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
AVORO CAPITAL ADVISORS LLC | 1,465,000 3.200% |
-885,267 (-37.67%) |
Filing History |
| 2022-02-11 10:06 am Purchase |
2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
AVORO CAPITAL ADVISORS LLC | 3,311,434 7.100% |
3,311,434 (New Position) |
Filing History |
| 2022-02-11 10:05 am Purchase |
2021-12-31 | 13G | Amicus Therapeutics, Inc. FOLD |
AVORO CAPITAL ADVISORS LLC | 18,500,000 6.600% |
7,300,000 (+65.18%) |
Filing History |
| 2022-02-11 10:05 am Purchase |
2021-12-31 | 13G | IO Biotech, Inc. IOBT |
AVORO CAPITAL ADVISORS LLC | 2,055,883 7.100% |
2,055,883 (New Position) |
Filing History |
| 2022-02-11 10:04 am Purchase |
2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
AVORO CAPITAL ADVISORS LLC | 8,555,555 8.900% |
8,555,555 (New Position) |
Filing History |
| 2022-02-11 10:04 am Purchase |
2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
AVORO CAPITAL ADVISORS LLC | 8,675,000 5.500% |
1,175,000 (+15.67%) |
Filing History |
| 2022-02-11 10:03 am Purchase |
2021-12-31 | 13G | Madrigal Pharmaceuticals, Inc. MDGL |
AVORO CAPITAL ADVISORS LLC | 1,425,000 8.300% |
200,000 (+16.33%) |
Filing History |
| 2022-02-11 10:03 am Purchase |
2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
AVORO CAPITAL ADVISORS LLC | 12,800,000 14.700% |
2,500,000 (+24.27%) |
Filing History |
| 2022-02-11 10:02 am Purchase |
2021-12-31 | 13G | United Therapeutics Corporation UTHR |
AVORO CAPITAL ADVISORS LLC | 3,035,000 6.700% |
185,000 (+6.49%) |
Filing History |
| 2022-02-11 10:01 am Sale |
2021-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
AVORO CAPITAL ADVISORS LLC | 695,000 7.100% |
-105,000 (-13.12%) |
Filing History |
| 2022-02-11 10:01 am Purchase |
2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
AVORO CAPITAL ADVISORS LLC | 3,235,000 8.800% |
2,858 (+0.09%) |
Filing History |
| 2022-02-11 10:01 am Purchase |
2021-12-31 | 13G | Mirati Therapeutics, Inc. MRTX |
AVORO CAPITAL ADVISORS LLC | 5,075,000 9.200% |
540,000 (+11.91%) |
Filing History |
| 2022-02-11 10:00 am Purchase |
2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
AVORO CAPITAL ADVISORS LLC | 4,985,000 9.700% |
2,185,000 (+78.04%) |
Filing History |
| 2021-11-24 3:48 pm Sale |
2021-11-22 | 13D | Acceleron Pharma Inc. XLRN |
AVORO CAPITAL ADVISORS LLC | 0 0.000% |
-4,476,100 (Position Closed) |
Filing History |
| 2021-10-05 12:30 pm Purchase |
2021-09-30 | 13D | Acceleron Pharma Inc. XLRN |
AVORO CAPITAL ADVISORS LLC | 4,476,100 7.300% |
4,476,100 (New Position) |
Filing History |
| 2021-08-30 5:27 pm Purchase |
2021-08-26 | 13D | Aadi Bioscience, Inc. AADI |
AVORO CAPITAL ADVISORS LLC | 2,211,752 10.700% |
2,211,752 (New Position) |
Filing History |
| 2021-06-04 08:30 am Purchase |
2021-05-27 | 13D | Aerpio Pharmaceuticals, Inc. ARPO |
AVORO CAPITAL ADVISORS LLC | 300,000 9.500% |
300,000 (New Position) |
Filing History |